Literature DB >> 2655764

Drug-induced jaundice.

J Neuberger.   

Abstract

A large number of drugs may be associated with impaired bile flow. Drug-associated cholestasis presents like other forms of cholestasis with pale stools, dark urine, pruritus and jaundice. Abdominal pain may be present in some instances and can be so severe as to lead to a false diagnosis of acute cholecystitis. Biochemically, drug-associated cholestasis resembles other forms of cholestasis although the presence of eosinophilia may suggest drug involvement. Many types of drug-induced cholestasis run a benign course with resolution of signs and symptoms within 3 months but occasionally the jaundice can take a year or more to resolve. Progression to cirrhosis is uncommon. Some patients may develop a syndrome resembling primary biliary cirrhosis. The mechanisms of drug-associated cholestasis are uncertain but may arise from alteration of bile formation within the hepatocyte or bile excretion at the level of the canaliculus or the extrahepatic ducts. Histological examination of the liver may be helpful in classifying the types of jaundice but the diagnosis of drug-induced cholestasis is usually one of temporal association and exclusion of other causes.

Entities:  

Mesh:

Year:  1989        PMID: 2655764     DOI: 10.1016/0950-3528(89)90010-9

Source DB:  PubMed          Journal:  Baillieres Clin Gastroenterol        ISSN: 0950-3528


  3 in total

1.  Glibenclamide-induced cholestasis.

Authors:  V N Tholakanahalli; A Potti; M F Heyworth
Journal:  West J Med       Date:  1998-04

2.  A novel miRNA inhibits metastasis of prostate cancer via decreasing CREBBP-mediated histone acetylation.

Authors:  Fubo Wang; Wei Zhang; Zijian Song; Maoyu Wang; Hanxiao Wu; Yang Yang; Rui Chen
Journal:  J Cancer Res Clin Oncol       Date:  2020-11-21       Impact factor: 4.553

3.  Analytical investigations of toxic p-phenylenediamine (PPD) levels in clinical urine samples with special focus on MALDI-MS/MS.

Authors:  Gero P Hooff; Nick A van Huizen; Roland J W Meesters; Eduard E Zijlstra; Mohamed Abdelraheem; Waleed Abdelraheem; Mohamed Hamdouk; Jan Lindemans; Theo M Luider
Journal:  PLoS One       Date:  2011-08-04       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.